SCHEMBL5134997

SCHEMBL5134997

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
TSHR P16473 4/20 0.44
HSD11B1 P28845 2/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 3/20 0.38
HSD17B10 Q99714 3/20 0.38
NR1H3 Q13133 3/20 0.38
PDE4B Q07343 2/20 0.37
CNR2 P34972 1/20 0.36
NR1H2 P55055 2/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
CYP3A4 P08684 2/20 0.36
ADORA2B P29275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072228 0.95 C5AR1 (0.46) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5135043 0.94 C5AR1 (0.46) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5136527 0.94 C5AR1 (0.46) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL651094 0.93 TSHR (0.50) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5135922 0.92 C5AR1 (0.49) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5137707 0.92 C5AR1 (0.43) C5AR1TSHRALDH1A1KDM4EHPGD
SCHEMBL5134746 0.91 C5AR1 (0.48) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5073888 0.91 C5AR1 (0.48) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5137501 0.91 C5AR1 (0.43) C5AR1TSHRHSD11B1ALDH1A1KDM4E
SCHEMBL5134969 0.89 C5AR1 (0.41) C5AR1TSHRHSD11B1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed